Literature DB >> 2685647

Motor complications associated with chronic levodopa therapy in Parkinson's disease.

J A Obeso1, F Grandas, J Vaamonde, M R Luquin, J Artieda, G Lera, M E Rodriguez, J M Martinez-Lage.   

Abstract

Fluctuations and dyskinesias are the 2 main motor complications associated with chronic levodopa therapy. Striatal denervation following degeneration of the substantia nigra dopaminergic projections is probably the major pathophysiologic mechanism underlying motor fluctuations. In addition, pathologic modification of striatal receptors, partially related to the nonphysiologic delivery of levodopa in a discontinuous pulsatile mode, may be responsible for the various types of dyskinesias and sudden "off" episodes. Drugs capable of providing a stable dopaminergic stimulation should be particularly useful for preventing the development of motor complications in patients not yet treated. At the other end of the clinical spectrum, patients with complex fluctuations are the least likely to improve with slow-release levodopa preparations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685647

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.

Authors:  Geoffrey B Varty; Robert A Hodgson; Annamarie J Pond; Michael E Grzelak; Eric M Parker; John C Hunter
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

3.  Surgery for Parkinson's disease.

Authors:  J A Obeso; J Guridi; J A Obeso; M DeLong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

4.  Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease.

Authors:  Vanina Dal Bello-Haas; Laura Klassen; M Suzanne Sheppard; Amy Metcalfe
Journal:  Physiother Can       Date:  2011-01-20       Impact factor: 1.037

Review 5.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 6.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 7.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 8.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

9.  Prospective cohort study of impulse control disorders in Parkinson's disease.

Authors:  Jesse Bastiaens; Benjamin J Dorfman; Paul J Christos; Melissa J Nirenberg
Journal:  Mov Disord       Date:  2013-01-02       Impact factor: 10.338

Review 10.  [Pharmacological treatment of motor symptoms in Parkinson's diseases].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.